Literature DB >> 14604821

Thrombin interaction with platelet membrane glycoprotein Ib alpha.

Frédéric Adam1, Marie-Christine Bouton, Marie-Geneviève Huisse, Martine Jandrot-Perrus.   

Abstract

The interaction of thrombin with platelet glycoprotein Ibalpha (GPIb alpha) is required for optimal platelet activation. The crystal structures of platelet GPIb alpha bound to thrombin reported by Dumas et al. and Celikel et al. both reveal the simultaneous interaction of GPIb alpha with thrombin exosites I and II but differ markedly regarding how the two proteins interact. The possible consequences on thrombus formation of thrombin interacting with GPIb alpha are discussed in light of these new data.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14604821     DOI: 10.1016/j.molmed.2003.09.009

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  4 in total

1.  Biophysical investigation of GpIbalpha binding to thrombin anion binding exosite II.

Authors:  T Michael Sabo; Muriel C Maurer
Journal:  Biochemistry       Date:  2009-08-04       Impact factor: 3.162

2.  Effect of Xiaoyu Zhixue Tablet on the expression of platelet membrane glycoprotein I b/IX/V complex in patients with chronic renal failure.

Authors:  You Qin; Lin Shen; Fu-rong Lu; Wei Shi; Jian-guo Liu
Journal:  Chin J Integr Med       Date:  2008-08-06       Impact factor: 1.978

3.  Expression of platelet membrane glycoprotein Ib/IX/V complex, a receptor of thrombin, in patients with hemorrhagic thrombopathy.

Authors:  Lin Shen; Di Shen; Rui Zhu; Min Zhu; Furong Lu; You Qin; Heng Fan
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-12-24

4.  In Surgical Colon Cancer Patients Extended-Duration Thromboprophylaxis (30 days) with the Highest Dose of Tinzaparin (4,500 IU s.c./q.d.) Normalizes the Postoperative VEGF Levels.

Authors:  Michail Mitsis; Panagiotis Koliou; Christina Bali; Evangelia Ntounousi; Vasileios Tatsis; Vasileios Nousias; Georgios D Lianos; Georgios Vartholomatos; Dimitrios Nastos
Journal:  J Cancer       Date:  2017-08-25       Impact factor: 4.207

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.